KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial. PMID 41537701 · Clin Cancer Res · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD). PMID 41422917 · Int J Radiat Oncol Biol Phys · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Prospective, randomized dose-escalation trial with proton-based radiation for skull base and cervical spine chondrosarcomas: 30-year outcomes from PROG 85-26. PMID 41414803 · Neuro Oncol · 2026-Apr-01 The study is a randomized trial reporting time-to-event efficacy results, but it lacks an explicit drug-containing intervention and does not clearly establish a definitive Phase III/IIIb or Phase II/III status.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase III Randomized Controlled Trial of Pyloroplasty Versus No Pyloroplasty in Patients Undergoing Minimally Invasive Esophagectomy or Robot-assisted Minimally Invasive Esophagectomy. PMID 41413794 · Ann Surg · 2026-Apr-01 干预为非药物单独策略,未满足药物干预要求。
H L B
旧查询独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial. PMID 41275977 · Int J Radiat Oncol Biol Phys · 2026-Apr-01 The report is a Phase III randomized trial in human oncology, but the intervention is non-drug-only (stereotactic vs. hypofractionated radiation therapy) and the primary endpoint is quality-of-life, not a time-to-event efficacy outcome (e.g., OS, PFS). Therefore, it does not meet the eligibility criteria for a drug-containing intervention with a primary/key secondary time-to-event endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Controlled trial of cervical cancer screening frequency among human-papillomavirus-vaccinated women. PMID 41203578 · Int J Cancer · 2026-Apr-01 The record describes a randomized trial in cervical cancer screening frequency among HPV-vaccinated women. It meets criteria for oncology, human, randomized, time-to-event, and original result. However, the intervention is a screening frequency (low- vs. high-intensity cytology), not a drug-containing therapeutic intervention. The trial phase is not explicitly stated as Phase III/IIIb or II/III; the metadata lacks definitive phase information. Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exclusion of patients with renal impairment from phase 3 randomized controlled trials in hematologic malignancies. PMID 41195829 · Int J Cancer · 2026-Apr-01 The record describes a meta-analytic study examining the exclusion of patients with renal impairment from phase 3 RCTs in hematologic malignancies. While it is oncology, human, randomized, phase 3, and involves drug interventions, it is not an original result report of a single trial. It lacks a primary time-to-event efficacy endpoint, as its outcomes are about trial design (eligibility criteria), not patient outcomes like OS or PFS. Therefore, it is excluded.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Postoperative Single-Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer With GammaPod Technology: A Phase 2 Clinical Trial. PMID 41161644 · Int J Radiat Oncol Biol Phys · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Electro-acupuncture for quality of life during adjuvant chemotherapy in gastric cancer: a randomized trial. PMID 41143548 · J Natl Cancer Inst · 2026-Apr-01 The study is excluded because the primary intervention under evaluation is electro-acupuncture (a non-drug modality), not a drug-containing intervention, which is a required criterion. Additionally, the trial phase is not definitively established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Five-Year Survival and Safety of SABR in Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer unfit for Concurrent Radio-chemotherapy: Focus on Patterns of Local Recurrence from the START-NEW-ERA Non-randomized Phase 2 Trial. PMID 40992670 · Int J Radiat Oncol Biol Phys · 2026-Apr-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The National Health Service-Galleri multicancer screening trial: explanation and justification of unique and important design issues. PMID 40795803 · J Natl Cancer Inst · 2026-Apr-01 The record is an explanatory article about the NHS-Galleri screening trial's design and justification. While it is an oncology RCT in humans with a definitive (Phase III) screening design, it does not meet two core eligibility criteria: (1) it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR), as its primary outcome is late-stage cancer incidence, which is a diagnostic/screening endpoint; and (2) the intervention is a diagnostic test, not a drug-containing intervention. Furthermore, it is not an original result report but a design rationale paper.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled Trial. PMID 40772617 · Ann Surg · 2026-Apr-01 The study is an oncology randomized trial with a primary OS endpoint, but it compares two surgical techniques for pancreatic cancer, not drug-containing interventions. Therefore, it does not meet the drug intervention criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessing the Impact of Media Coverage of the NordICC Trial on Public Perspectives on Colonoscopy for Colorectal Cancer Screening. PMID 39907707 · J Clin Gastroenterol · 2026-Apr-01 The record describes a survey study assessing public perception of media coverage about a cancer screening trial (NordICC). While it is a randomized study in an oncology context, it does not meet key eligibility criteria: it is not a clinical trial of a drug intervention (the 'intervention' is a media article), it is not a Phase III/IIIb or Phase II/III trial, and it has no time-to-event efficacy endpoint. The primary outcome is a change in intent to undergo colonoscopy, which is a behavioral/attitudinal measure, not a clinical survival or progression endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Positive Resection Margins on Recurrence and Survival After Resection and Adjuvant Chemotherapy in Pancreatic Cancer: Results of the PRODIGE 24-CCTG PA-6 Randomized Controlled Trial. PMID 39041211 · Ann Surg · 2026-Apr-01 The record describes a secondary analysis (prognostic impact of resection margins) of a phase III randomized trial (PRODIGE 24/CCTG PA-6). While the parent trial is eligible, this specific report is a secondary analysis focusing on prognostic factors, not the primary efficacy comparison of the randomized intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of a Multidimensional Digital Health Intervention on Quality of Life in Breast Cancer Survivors: A Randomized Controlled Trial. PMID 42361286 · JCO Clin Cancer Inform · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Magnetic resonance imaging-guided radiotherapy for prostate cancer: A systematic review of the literature. PMID 42229011 · Cancer Radiother · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. PMID 42181314 · Cureus · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Serum Biomarkers and CT-Derived Muscle Indices in Sarcopenia Associated with Pancreatic Neoplasm: A Comparative Clinical Study. PMID 42084250 · Chirurgia (Bucur) · 2026-Apr The study is a randomized prospective biomarker and imaging study comparing patients with pancreatic neoplasm and sarcopenia to controls. While it involves human oncology patients and has a randomized design, it does not contain a drug-containing intervention (it is an observational/diagnostic biomarker study) and does not report a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, etc. The study's focus is on diagnostic/prognostic biomarkers and sarcopenia assessment, not the efficacy of a therapeutic drug.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Induction chemotherapy plus bevacizumab or radiotherapy in N2 non-squamous non-small cell lung cancer: 5-year results of a randomized phase 2 trial. PMID 42079970 · JTCVS Open · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of Once-Daily Macitentan 75 mg on the Pharmacokinetics of Sildenafil, Riociguat, or Rosuvastatin in Healthy Male Participants. PMID 42023995 · J Clin Pharmacol · 2026-Apr The record describes a Phase I pharmacokinetic study in healthy volunteers for pulmonary arterial hypertension, not an oncology trial. It lacks a time-to-event efficacy endpoint and is not a definitive randomized trial in cancer patients.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Impact of Endoscopic Ultrasound and Multidisciplinary Team Evaluation on the Management of Pancreatic Cystic Lesions. PMID 42023483 · United European Gastroenterol J · 2026-Apr The record is a randomized, crossover study evaluating diagnostic accuracy and cognitive bias in multidisciplinary team review of pancreatic cystic lesions, not a drug intervention trial for cancer treatment with time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Web-Based Cognitive Rehabilitation for Patients With Aggressive Lymphoma With Perceived Cognitive Impairment: A Randomised Pilot Study. PMID 42012802 · Psychooncology · 2026-Apr The study is an oncology randomized trial with original results, but it is excluded because it is a pilot study (not Phase III/IIIb or definitive Phase II/III), involves a non-drug intervention (cognitive rehabilitation), and does not have a time-to-event efficacy endpoint (primary outcomes are feasibility, neuropsychological tests, and patient-reported outcomes).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A novel methodology using direct patient contact and UK national registries to collect long-term data from randomised trials: TARGIT-X - an extended follow-up study of the TARGIT-A trial of targeted intraoperative radiotherapy for breast cancer. PMID 42011087 · Health Technol Assess · 2026-Apr The report is a methodology and feasibility study for collecting long-term follow-up data from an existing randomized trial (TARGIT-A). It does not report the primary efficacy results (e.g., OS, local control) of the original trial with a drug intervention. The intervention is radiotherapy (a procedure), not a drug. Therefore, it fails the required criteria for drug intervention and time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Rezvilutamide plus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer patients after progression on abiraterone: A multi-centre, open-label, phase II trial. PMID 41987598 · Clin Transl Med · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial. PMID 41986500 · Nat Cancer · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Keynote-177 Randomized Controlled Trial of First-line PD-1 Blockade for Microsatellite-High or Mismatch Repair-Deficient Advanced Colorectal Cancer: Potential Consequences of the Cross-Over Trial Design and Related Issues. PMID 41980913 · Cancer Med · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trial. PMID 41962307 · ESMO Open · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial. PMID 41962306 · ESMO Open · 2026-Apr The record describes a secondary analysis of patient-reported outcomes and qualitative interviews from a Phase III randomized drug trial. It does not report the primary or key secondary time-to-event efficacy results (e.g., OS, PFS) of the trial itself, which are required for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Missingness in Eligibility Criteria for Target Trial Emulation in EHR With Survival Outcomes. PMID 41944336 · Stat Med · 2026-Apr This is a methodological study about handling missing data in target trial emulation using EHR, not a report of an original randomized clinical trial. While it mentions an oncology context and survival outcomes, it is not a clinical trial report with drug intervention results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study. PMID 41938023 · Lancet Reg Health West Pac · 2026-Apr 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
B
影子组漏检补回 eligibleexplicit_phase3_randomized confirmed 1 Figure · 4 Panel · risk visible
Lenalidomide Plus Dexamethasone as FIRST-Line Therapy in Transplant-Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non-Interventional Study FIRST-NIS and Comparison With the FIRST Pivotal Phase III Clinical Trial. PMID 41927857 · Cancer Med · 2026-Apr The study is a prospective, non-interventional (observational) study comparing real-world outcomes to a previous pivotal trial. While it reports Phase III and time-to-event endpoints with a drug intervention, it lacks the core requirement of being a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial. PMID 41926962 · Lancet Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study. PMID 41926960 · Lancet Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. PMID 41912809 · Nat Med · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma. PMID 41864163 · ESMO Open · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Mortality Predictions Including Pre-Admission Functional Status in ICU Patients With Delirium-A Substudy of the AID-ICU Trial. PMID 41863137 · Acta Anaesthesiol Scand · 2026-Apr The record is a substudy of the AID-ICU trial (delirium in ICU), which is not an oncology trial, does not involve a drug-containing cancer intervention, and does not present time-to-event efficacy results for an anti-cancer agent. It is a predictive modeling study, not a randomized trial comparing interventions for a malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer. PMID 41861752 · ESMO Open · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma. PMID 41813900 · Nature · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer. PMID 41812623 · ESMO Open · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia? PMID 41803403 · Leukemia · 2026-Apr The study is an original, randomized, oncology trial with a drug intervention and time-to-event endpoint (OS), but it fails the definitive phase criterion. The metadata does not confirm Phase III/IIIb or Phase II/III status, and the provided text does not state the trial phase. Furthermore, the primary focus is a biomarker/prognostic analysis (post-hoc landmark analysis of monocytes and granulocytes) rather than a primary efficacy report of the randomized comparison. The title and abstract frame it as a prognostic study, not a trial efficacy report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study. PMID 41800821 · Pharmacotherapy · 2026-Apr The trial is not eligible because the phase is not established as Phase III/IIIb or Phase II/III, and the primary endpoint is a neurotoxicity endpoint, not a malignancy efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
BEAT-BK: An Adaptive, Randomized Controlled Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Kidney-pancreas Transplantation Recipients (BEAT-BK) Study Protocol. PMID 41799026 · Transplant Direct · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A pre-operative two-week very low-calorie diet to reduce steatosis before liver resection (RESOLVE): A multi-centre randomised controlled feasibility trial. PMID 41797062 · Eur J Surg Oncol · 2026-Apr The study is a feasibility trial evaluating a very low-calorie diet (non-drug intervention) before liver resection for liver neoplasms. It is not a Phase III or definitive randomized trial, and no time-to-event efficacy endpoints (e.g., OS, PFS) or Kaplan-Meier analyses are reported. The intervention is not drug-containing.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial). PMID 41763966 · Ann Rheum Dis · 2026-Apr The study is a randomized Phase III trial of a drug (ozoralizumab, a TNF inhibitor) in rheumatoid arthritis, not a human malignant neoplasm. While it meets criteria for randomized, phase 3, human, drug intervention, and original result, it is excluded because it is non-oncology and the primary endpoint is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, etc.).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Medical thoracoscopy with talc poudrage and indwelling pleural catheter insertion versus medical thoracoscopy with talc poudrage alone for patients with symptomatic malignant pleural effusion (TACTIC): a randomised, controlled phase 3 trial. PMID 41763237 · Lancet Respir Med · 2026-Apr Study is a Phase III randomized trial in oncology with human participants and an original primary result, but it does not meet the core eligibility criteria because it lacks a primary/key time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR) and its intervention is a medical device (IPC) combined with a procedure, not a drug-containing intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical efficacy of Xiaotan Sanjie decoction in treating gastric cancer with peritoneal metastases: A study protocol for a randomized controlled trial. PMID 41756199 · Contemp Clin Trials Commun · 2026-Apr 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer. PMID 41731117 · Br J Cancer · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudy. PMID 41730506 · Diabetes Res Clin Pract · 2026-Apr The record describes a pharmacogenetic substudy of the FIELD trial. While the FIELD trial itself is a Phase III randomized trial of a drug (fenofibrate) with time-to-event efficacy endpoints, the specific study is not an oncology trial. Its primary outcomes are diabetic vascular complications and mortality; cancer-related mortality is only one of several secondary mortality endpoints analyzed in the context of a genetic variant. Therefore, it does not meet the core requirement of being a report on an oncology (human malignant neoplasm) clinical trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The differential effects of social support on quality of life in head and neck cancer patients in the United States and China. PMID 41723882 · Eur J Oncol Nurs · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma. PMID 41714403 · Leukemia · 2026-Apr The record describes a translational/biomarker study (miR-29 in follicular lymphoma) that uses a published RCT (SWOG S0016) as a validation cohort for survival correlations. It is not a report of the original, formal, drug-containing, Phase III/IIIb or Phase II/III randomized trial's efficacy results. The drug intervention criterion is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -